Hemodynamic Effects of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With Peripheral Arterial Disease

A Phase 2 Double-blind, Placebo-controlled Study to Evaluate Hemodynamic Effects of Intramuscular Injection of Human Placenta-derived Cells (Pda-002) in Subjects Who Have Diabetic Foot Ulcer With Peripheral Arterial Disease

Study PDA-002-DFU-003 is a Phase 2, multicenter, randomized, double blind, placebo-controlled, dose range finding study in subjects who have diabetic foot ulcer (DFU) with peripheral arterial disease (PAD). The study will enroll approximately 24 subjects. This study will investigate the hemodynamic effects, clinical efficacy, and safety of 3 monthly intramuscular (IM) injections of PDA-002 in subjects who have DFU with PAD.

Study Overview

• Status: Withdrawn
• Conditions: Diabetic Foot; Peripheral Arterial Disease
• Intervention / Treatment: Drug: Placebo; Drug: PDA-002

Detailed Description

Although the study protocol was developed, the study was withdrawn prior to enrollment. Four subjects were screened but did not meet eligibility criteria, and no participants were enrolled.

• Study Type: Interventional
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Pennsylvania
    • Philadelphia, Pennsylvania, United States, 19104
      • University of Pennsylvania Health Systems

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Males and females, at least 18 years of age or older at the time of signing the informed consent document.
2. Diabetes mellitus Type 1 or Type 2.
3. Diabetic foot ulcer with severity of Grade 1 (full thickness only) or Grade 2 on the Wagner Grading Scale of greater than one month duration which has not adequately responded to conventional ulcer therapy.

4. Subjects who meet one or more of the following criteria of arterial insufficiency in the foot with the index ulcer:

   1. Peripheral arterial disease with ABI ≥ 0.40 and ≤ 0.80 or TBI ≥0.30 and ≤ 0.65.
   2. Transcutaneous oxygen measurement between 20 to 40 mmHg.
5. No planned revascularization or amputation over the next 3 months after screening visit, in the opinion of the investigator.
6. Dosing should not begin until at least 14 days after a failed reperfusion intervention and at least 30 days after a successful reperfusion intervention

Exclusion Criteria:

1. Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study, at the discretion of the investigator.
2. Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he or she were to participate in the study, at the discretion of the investigator.
3. Pregnant or lactating females.
4. Subjects with a body mass index > 40 mg/m2 at Screening.
5. Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2 at Screening calculated using the Modification of Diet in Renal Disease Study equation or history of eGFR decline > 15 mL/min/1.73 m2 in the past year.
6. Untreated chronic infection or treatment of any infection with systemic antibiotics,including the ulcer site. Subject must be antibiotic free within 1 week prior to dosing with Investigational Product (IP).
7. Known osteomyelitis or infection or cellulitis at or adjacent to the index ulcer.
8. Limb pain at rest due to limb ischemia.
9. Uncontrolled hypertension (defined as diastolic blood pressure > 100 mmHg or systolic blood pressure > 180 mmHg during Screening at 2 independent measurements taken while subject is sitting and resting for at least 5 minutes).
10. Poorly controlled diabetes mellitus (hemoglobin A1c >12% or a screening serum glucose of ≥ 300 mg/dL).
11. Untreated proliferative retinopathy.
12. History of malignant ventricular arrhythmia, Canadian Cardiovascular Society (CCS) Class III-IV angina pectoris, myocardial infarction/PCI (percutaneous coronary intervention)/CABG (coronary artery bypass graft) in the preceding 6 months prior to signing the Informed Consent (ICF),pending coronary revascularization in the following 3 months, transient ischemic attack/cerebrovascular accident in the preceding 6 months, prior to signing the ICF and/or New York Heart Association [NYHA] Stage III or IV congestive heart failure.
13. Abnormal ECG: new right bundle branch block (BBB) ≥ 120 msec in the preceding 3 months prior to signing the ICF.
14. Uncontrolled hypercoagulation syndrome.
15. Life expectancy less than 2 years due to concomitant illnesses.
16. In the opinion of the investigator, the subject is unsuitable for cellular therapy.
17. History of malignancy within 5 years prior to signing the ICF except basal cell or squamous cell carcinoma of the skin or remote history of cancer now considered cured or positive Pap smear with subsequent negative follow-up.
18. History of hypersensitivity to any of the components of the product formulation (including bovine or porcine products, dextran 40, and dimethyl sulfoxide [DMSO]).
19. Subject has received an investigational agent -an agent or device not approved by the US Food and Drug Administration (FDA) for marketed use in any indication- within 90 days (or 5 half-lives, whichever is longer) prior to treatment with study therapy or planned participation in another therapeutic study prior to the completion of this study.
20. Subject has received previous investigational gene or cell therapy.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: PDA-002 -3x10^6 cells; Subjects will be treated with Investigational Product (IP) administered intramuscular (IM) on Study Days 1, 29 and 57.	Drug: PDA-002; 3 million dose of PDA-002
Experimental: PDA-002 - 30X10^6 cells; Subjects will be treated with IP administered IM on Study Days 1, 29 and 57.	Drug: PDA-002; 3 million dose of PDA-002
Placebo Comparator: Placebo; Subjects will be treated with Placebo administered IM on Study Days 1, 29 and 57.	Drug: Placebo; Placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Ankle-brachial Index (ABI)	The ankle brachial index is the ratio of the measurement of the blood pressure in the ankle and the arm.	Approximately 1 year
Transcutaneous oxygen measurement (TCOM)	Transcutaneous oxygen measurement measures the oxygen flow in vessels beneath the skin surface	Approximately 1 year

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Adverse Events (AEs)	Number of participants with adverse events	Approximatly 1 year
Ulcer closure	Ulcer closure is defined as skin closure of the index ulcer without drainage or need for dressing.	Approximatly 1 year
Complete wound closure of the index ulcer	Complete wound closure is defined as closure of the index ulcer and retaining wound closure for the subsequent 4 weeks.	Approximatly 1 year
Number of ulcers	The total number of non index ulcers will be collected	Approximatly 1 year
Size of ulcers	The area of each ulcer will be collected.	Approximatly 1 year
50% closure of the index ulcer	The time to when the ulcer has closed 50 % will be collected.	Approximatly 1 year
Time to major amputation (above the ankle) of treated leg	The time to a major amputation (above the ankle) will be collected.	Approximatly 1 year
Wagner Grading Scale	The extent of the ulcer will be collected using a standard scale for ulcer assessment.	Approximatly 1 year
Rutherford Criteria	The extent of symptoms associated with decreased limb perfusion will be collected using a standard scale.	Approximately 1 year
Leg Rest Pain Score Visual Analog Scale (VAS)	Pre and Post treatment Limb Pain level will be assessed using a VAS	Approximately 1 year
Patient Global Impression of Change in Neuropathy (PGICN)	Subjects will be assessed for symptoms of diabetic neuropathy using a standard scale.	Approximately 1 year

Collaborators and Investigators

• Sponsor: Celularity Incorporated
• Investigators: Study Director: sharmila koppisetti, Celularity Incorporated

Study record dates

Study Major Dates

• Study Start (Actual): June 1, 2015
• Primary Completion (Actual): January 1, 2016
• Study Completion (Actual): January 6, 2016

Study Registration Dates

• First Submitted: April 21, 2015
• First Submitted That Met QC Criteria: May 28, 2015
• First Posted (Estimated): June 2, 2015

Study Record Updates

• Last Update Posted (Actual): April 29, 2026
• Last Update Submitted That Met QC Criteria: April 24, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Keywords: Peripheral arterial disease; Randomized; Phase 2; Diabetic Foot Ulcer; PDA-002
• Additional Relevant MeSH Terms: Endocrine System Diseases; Vascular Diseases; Cardiovascular Diseases; Diabetes Mellitus; Diabetic Angiopathies; Diabetes Complications; Skin Diseases; Skin Ulcer; Leg Ulcer; Diabetic Neuropathies; Atherosclerosis; Arteriosclerosis; Arterial Occlusive Diseases; Peripheral Vascular Diseases; Foot Ulcer; Skin and Connective Tissue Diseases; Diabetic Foot; Peripheral Arterial Disease
• Other Study ID Numbers: CCT-PDA-002-DFU-003